We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Uniqure NV | TG:UQ1 | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|
| 0.355 | 2.04% | 17.75 | 307 | 16:49:40 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 17.745 | 18.015 | 17.925 | 17.575 | 17.575 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:43:56 | 2 | 17.75 | EUR |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/12/2024 | 12:05 | UKREG | uniQure Announces Alignment with FDA on Key Elements of Accelerated.. |
| 21/11/2024 | 12:05 | UKREG | uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical.. |
| 05/11/2024 | 12:05 | UKREG | uniQure Announces Third Quarter 2024 Financial Results and Highlights.. |
| 15/10/2024 | 11:05 | UKREG | uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of.. |
| 23/9/2024 | 11:05 | UKREG | uniQure Announces Orphan Drug Designation Granted to AMT-191 for the.. |
| 15/8/2024 | 11:05 | UKREG | uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of.. |
| 01/8/2024 | 11:05 | UKREG | uniQure Announces Second Quarter 2024 Financial Results and Provides.. |
| 23/7/2024 | 11:05 | UKREG | uniQure Announces Closing of Sale of Manufacturing Facility to Genezen |
| 09/7/2024 | 11:05 | UKREG | uniQure Announces Positive Interim Data Update Demonstrating Slowing of.. |
Uniqure NV (UQ1) Share Charts1 Year Uniqure NV Chart |
|
1 Month Uniqure NV Chart |
Intraday Uniqure NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
